What type of study is this?

This is a Literature Review study.

December 8, 2025BloodOpen Access

Utilization and outcomes of erythropoietin stimulating agents in sickle cell disease patient: A real world data analysis

View Full Paper

Ask AI

Bookmark

Authors

DDDevashish DesaiHospital of St. Francis Xavier DPDeevyashali ParekhSUNY Upstate Medical University

Discussion

Member takes

Implication

Real-world data analysis reveals erythropoietin stimulating agents impact sickle cell disease outcomes, indicating risks of ischemic stroke and cardiac ischemia.

Key Points

Sickle cell disease patients using erythropoietin stimulating agents had higher all-cause mortality compared to non-users, emphasizing risks.
Among 19,143 identified patients, 9.14% received EPO, showing significant differences in demographics and care received.
Propensity score matching was used to analyze the outcomes of EPO in sickle cell disease patients with chronic kidney disease.
Findings call for careful consideration of the risks associated with erythropoietin stimulating agents and their use in treatment.

Cite This Study

Desai et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4b3 https://doi.org/10.1182/blood-2025-1197

View Full Paper

Ask AI

Bookmark

Implication

Real-world data analysis reveals erythropoietin stimulating agents impact sickle cell disease outcomes, indicating risks of ischemic stroke and cardiac ischemia.

Utilization and outcomes of erythropoietin stimulating agents in sickle cell disease patient: A real world data analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Utilization and outcomes of erythropoietin stimulating agents in sickle cell disease patient: A real world data analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider